No Data
No Data
Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.
Grant options under the stock option plan and rewards under the long-term incentive plan of hutchmed (china).
Hutchmed (China) (00013) announced that on August 5, 2024, it had granted stock options under the stock option plan adopted by Hutchmed (China) in 2015 and awards under the long-term incentive plan adopted by Hutchmed (China) in 2015. Hutchmed (China) granted its stock options under the stock option plan to Dr. Weiguo Su (Executive Director, CEO and Chief Scientific Officer), a person responsible for complying with the UK market abuse regulations, subject to performance targets. A total of 1.4058 million ordinary shares with a nominal value of USD 0.10 each in the company's share capital are available for subscription, subject to the acceptance of the grantee.
CICC: The pharmaceutical sector has entered a value investment range, focusing on the domestic innovative drug industry chain and going overseas.
China International Capital Corporation released a research report stating that after three years of systematic adjustment, the pharmaceutical sector has entered the range of value investment.
6-K: Report of foreign private issuer (related to financial reporting)
HUTCHMED Incentivizes Talent With New Share Options
Hutchmed (China) (00013.HK): Granted stock options under the share option scheme and rewards under the long-term incentive plan.
Hutchmed (China) (00013.HK) announced on August 6th that it has granted options under the share option scheme ("Option Scheme") adopted by Hutchmed (China) in 2015 and awards under the long-term incentive plan ("LTIP") adopted by Hutchmed (China) in 2015 on August 5th, 2024. Hutchmed (China) granted options under its share option scheme to Wei-guo Su (Executive Director, CEO and Chief Scientific Officer), subject to performance targets; provided that the offeree accepts, to subscribe for a total of 1,405,767 shares of the company's stock with a face value of 0.10 per share.
No Data
DailyHunt : Do you think is ready?
Momentum Trader OP DailyHunt : Already Bo from pivot. Don’t chase high!